Advances in Endocrine Therapy for Postmenopausal Metastatic Breast Cancer-Reference-Cited by-同舟云学术

Advances in Endocrine Therapy for Postmenopausal Metastatic Breast Cancer

Published:2018 Issue: Volume: Page:141-154
ISSN:0927-3042
Container-title:Optimizing Breast Cancer Management
language:
Short-container-title:

Author:

Flaum Lisa E.,Gradishar William J.

Publisher

Springer International Publishing

Link

http://link.springer.com/content/pdf/10.1007/978-3-319-70197-4_9

Reference50 articles.

1. Beatson G (1895) On the treatment of inoperable cases of carcinoma of the mamma-suggestions for a new method of treatment with illustrative cases. Lancet 2:104–107

2. Morgan LR Jr, Schein PS, Woolley PV et al (1976) Therapeutic use of tamoxifen in advanced cancer, correlation with biochemical parameters. Cancer Treat Rep 60:1437–1443

3. Rose C, Mouridsen HT (1984) Treatment of advanced breast cancer with tamoxifen. Recent Results Cancer Res 91:230–242

4. Muss HB, Case LD, Atkins JN et al (1994) Tamoxifen versus high dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. J Clin Oncol 12:1630–1638

5. Buzdar A, Jonat W, Howell A et al (1996) Anastrozole, a potent and selective aromatase inhibitor versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 14:2000–2011

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapy for Hormone Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer Following Treatment Progression via CDK4/6 Inhibitors: A Literature Review;Breast Cancer: Targets and Therapy;2024-04

2. The use of ribociclib in real clinical practice: results of a single-center observational retrospective study;Meditsinskiy sovet = Medical Council;2024-01-17

3. Bruceine D and Narclasine inhibit the proliferation of breast cancer cells and the prediction of potential drug targets;PLOS ONE;2024-01-12

4. Search for predictors of the efficiency of treatment with CDK4/6 inhibitors with HR+/HER2 metastatic breast cancer;Onkologiya. Zhurnal imeni P.A.Gertsena;2023

5. The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time;Journal of Cancer Research and Clinical Oncology;2021-07-09